This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Dasatinib overcomes glucocorticoid resistance in B-cell acute lymphoblastic leukemia
Nature Communications Open Access 22 May 2023
-
Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia
Leukemia Open Access 02 February 2021
-
Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia
British Journal of Cancer Open Access 15 June 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hunger SP, Mullighan CG . Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood 2015; 125: 3977–3987.
Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470–480.
Kuiper RP, Waanders E, van der Velden VH, van Reijmersdal SV, Venkatachalam R, Scheijen B et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 2010; 24: 1258–1264.
Klumper E, Pieters R, Veerman AJ, Huismans DR, Loonen AH, Hahlen K et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 1995; 86: 3861–3868.
Kaspers GJ, Pieters R, Van Zantwijk CH, Van Wering ER, Van Der Does-Van Den Berg A, Veerman AJ . Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood 1998; 92: 259–266.
Dordelmann M, Reiter A, Borkhardt A, Ludwig WD, Gotz N, Viehmann S et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999; 94: 1209–1217.
Vitanza NA, Zaky W, Blum R, Meyer JA, Wang J, Bhatla T et al. Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance. Pediatr Blood Cancer 2014; 61: 1779–1785.
Sionov RV, Spokoini R, Kfir-Erenfeld S, Cohen O, Yefenof E . Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis. Adv Cancer Res 2008; 101: 127–248.
Bachmann PS, Piazza RG, Janes ME, Wong NC, Davies C, Mogavero A et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood 2010; 116: 3013–3022.
Paugh SW, Bonten EJ, Savic D, Ramsey LB, Thierfelder WE, Gurung P et al. NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat Genet 2015; 47: 607–614.
Piovan E, Yu J, Tosello V, Herranz D, Ambesi-Impiombato A, Da Silva AC et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell 2013; 24: 766–776.
Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011; 471: 235–239.
Jones CL, Bhatla T, Blum R, Wang J, Paugh SW, Wen X et al. Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model. J Biol Chem 2014; 289: 20502–20515.
Ferreiros-Vidal I, Carroll T, Taylor B, Terry A, Liang Z, Bruno L et al. Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B-cell differentiation. Blood 2013; 121: 1769–1782.
Joshi I, Yoshida T, Jena N, Qi X, Zhang J, Van Etten RA et al. Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia. Nat Immunol 2014; 15: 294–304.
Acknowledgements
We thank Meinrad Busslinger for providing us with the Ikzf1Neo mice and William Carroll for the UOCB1 cell line. This study was funded by the KiKa foundation (Stichting Kinderen Kankervrij; Grants 2009-55, 2010-77), in part by the Dutch Cancer Society (KWF grants KUN2009-4298 to RPK and KUN2012-5366 to EW) and the Stichting KOC Nijmegen.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Marke, R., Havinga, J., Cloos, J. et al. Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia. Leukemia 30, 1599–1603 (2016). https://doi.org/10.1038/leu.2015.359
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.359
This article is cited by
-
Dasatinib overcomes glucocorticoid resistance in B-cell acute lymphoblastic leukemia
Nature Communications (2023)
-
Allogeneic hematopoietic stem cell transplantation overcome the poor prognosis of patients with IKZF1plus CD20–a very high-risk subtype in B-cell acute lymphoblastic leukemia
Bone Marrow Transplantation (2022)
-
Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia
Leukemia (2021)
-
Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia
British Journal of Cancer (2020)
-
Genome-wide methylation profiling identified novel differentially hypermethylated biomarker MPPED2 in colorectal cancer
Clinical Epigenetics (2019)